<DOC>
	<DOCNO>NCT00134719</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity Hib-MenCY-TT vaccine compare control group receive license Hib MenC conjugate vaccine , administer 2 , 4 , 6 , 12 15 month age . Co-administration live , attenuated measles , mumps , rubella combination vaccine ; live , attenuate varicella vaccine assess administration booster dose . The Protocol Posting update order comply FDA Amendment Act , September 2007 .</brief_summary>
	<brief_title>Hib-MenCY-TT Vaccine Study Compared Licensed Hib Meningococcal Serogroup C Conjugate Vaccines</brief_title>
	<detailed_description>The study conduct 2 stage : 3-dose primary vaccination 2 , 4 6 month age booster vaccination 12 15 month age . All subject 3 blood sample take . Half subject group blood sample take prior administration third dose primary vaccination half subject group blood sample take one month third vaccine dose primary vaccination phase . In addition , subject group blood sample take 42 day administration booster dose .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . A male female , include , 6 12 week age time first vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Born gestation period 36 42 week . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . Planned administration/ administration vaccine foreseen study protocol within 30 day first dose vaccine ( ) . Previous vaccination Neisseria meningitidis , Haemophilus influenzae type b , diphtheria , tetanus , pertussis , poliovirus , and/or Streptococcus pneumoniae ; one previous dose hepatitis B vaccine . Vaccination hepatitis B birth accept ( although mandatory ) . Influenza vaccination allow 30 day administration third vaccine dose 30 day precede booster dose . History Neisseria meningitidis , Haemophilus influenzae type b , diphtheria , tetanus , pertussis , hepatitis B , poliovirus , Streptococcus pneumoniae and/or varicella invasive disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine ( ) , include dry natural latex rubber , tetanus toxoid , diphtheria toxoid , neomycin , polymyxin . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment . Administration immunoglobulins and/or blood product since birth plan administration study period . Additional specific criterion booster part study History previous vaccination measles , mumps , rubella varicella . Previous booster vaccination Hib meningococcal serogroup C vaccine since last visit primary phase .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Invasive Hib &amp; N. meningitidis disease</keyword>
</DOC>